Appointment dossier — Serous Carcinomas
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Serous Carcinomas
Compounds named in the cited literature for Serous Carcinomas, labeled by the strongest evidence found:
- prophylactic oophorectomy — Named in the literature
- risk-reducing salpingectomy + delayed oophorectomy — Named in the literature
- risk-reducing salpingo-oophorectomy — Named in the literature
Open recruiting trials (18)
- NCT05150691 · Phase 1 / Phase 2 — A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (United States)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT06792552 · Phase 1 — A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors (United States)
- NCT04575935 · Phase 3 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (United States)
- NCT06617897 · Phase 3 — Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery (United Kingdom)
- NCT07795749 · Phase 2 — Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) (United States)
- NCT06639074 · Phase 2 — Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (United States)
- NCT07139977 · Phase 2 — Study of EV for Recurrent Endometrial Carcinoma (United States)
- NCT04518501 · Phase 1 / Phase 2 — Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer (China)
- NCT06369155 · Phase 2 — Azenosertib in Uterine Serous Carcinoma: Biomarker Study (United States)
- NCT07693452 · Phase 2 — Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms (United States)
- NCT06207305 · Phase 1 / Phase 2 — A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma (United States)
- NCT04716686 · Phase 2 — Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma (China)
- NCT07658196 · Phase 1 — TLR9 Immunotherapy for Peritoneal Carcinomatosis (United States)
- NCT06476808 · Phase 1 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. (United States)
- NCT05950464 · Phase 1 — Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (United States)
- NCT07341360 · Early Phase 1 — Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei (Norway)
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei (China)
Most-relevant first: trials that name Serous Carcinomas, then broader trials you may still qualify for. 69 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT05150691), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?